Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation

药物研究与创新卓越生物医学研究中心

• 批准号: 10569658
• 负责人: Jon Scott Thorson
• 金额: $ 226.01万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569658
• 关键词: Address; Area; Biology; Biomedical Research; Cardiovascular Diseases; Centers of Research Excellence; Chemicals; Clinical; Collaborations; Communicable Diseases; Communication; Core Facility; Development; Devices; Discipline; Disease; Education; Environment; Faculty; Fostering; Funding; Goals; Health; Infrastructure; Institution; Kentucky; Malignant Neoplasms; Mentors; Mentorship; Modeling; Molecular Medicine; Organic Synthesis; Outcome; Pharmacologic Substance; Pharmacy facility; Phase; Productivity; Research; Research Personnel; Research Project Grants; Research Support; Science; Scientist; Testing; Therapeutic; Translational Research; Translations; Universities; Validation; career development; clinical application; college; experience; faculty research; innovation; interdisciplinary collaboration; interest; multidisciplinary; pre-clinical; pre-clinical research; prevent; tool

PROJECT SUMMARY/ABSTRACT - OVERALL We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI will initially support four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and cardiovascular disease). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

项目摘要/摘要 - 总体 我们建议在药品研究中建立一个生物医学研究卓越中心（COBRE） 和英国肯塔基大学的创新。 CPRI将成为一个综合的多学科中心 专注于翻译化学生物学[化学生物学联系（化学生物学的应用） 开发经过验证的探针/模型以提高我们对生物学的理解的原则）和药物 科学（使用药物原理的应用推进未满足的潜在客户/材料/设备 临床需求）。毛绒将利用和发展独特的转化化学生物学研究支持 促进初级教师心态和职业发展的基础设施/专业知识，创新的生物医学 研究探针/工具/模型/材料开发和验证以及潜力的早期进步 “可翻译”资产。将在第一阶段开发和实施的关键脚底基础架构包括CPRI 行政核心和两个研究支持核心（翻译核心和计算核心）和 毛绒还将进一步发展并利用分子医学有机合成核心的毛线 支持CPRI初级教师项目/飞行员。 CPRI最初将支持四名杰出的初级调查员 在三个治疗区域（癌症，传染病和心血管疾病）中工作。 我们的总体假设是CPRI的翻译化学生物学重点提出了独特的独特 英国平台至：i）来自广泛，应用和 临床学科； ii）促进发展新的有影响力的问题/工具/模型并提高创新性 跨学科研究； iii）弥合基础学术研究发现与 通过教育，指导和主要支持基础设施进行商业/临床应用。 CPRI独特的重点 关于翻译化学生物学和早期翻译，填补了许多英国许多英国的临床前研究差距 杰出的研究中心在战略上专注于理解，治疗和预防主要疾病 这导致肯塔基州的健康挑战不成比例。预期的毛关系包括 英国初级教师的数量和多样性的增加，从事翻译化学生物学研究和 为开发和采用创新的生物医学问题/工具/型号/材料，新的可持续性，准备好准备好准备 英国翻译化学生物学研究支持基础设施和能力，数量增加 英国初级教师拥有独立的研究资金，并提高了可能“可翻译”英国的数字 临床前资产。